Northwest Biotherapeutics, Inc. (NWBO) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Bethesda, MD, アメリカ. 現CEOは Linda F. Powers.
NWBO を有する IPO日 2001-12-14, 25 名の正社員, に上場 Other OTC, 時価総額 $308.14M.
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
